Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

New biomarkers for response to immunotherapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.07.17
Views: 668

Prof Antoni Ribas - University of California, Los Angeles, USA

Prof Ribas speaks with ecancer at WIN 2017 about "the canary in the mine" of PDL-1 expression on tumour cells, and their response to checkpoint therapy.

He notes the off-target toxicities of ipilimumab, and the rationale for combining therapies to increase T cell infiltration beyond CTLA-4.

Prof Ribas notes the importance of the tumour microbiome in determining immunotherapy response, and the differing outcomes of adjuvant vs neoadjuvant staging.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence